Biomarkers for Alzheimer's: The sequel of an original model

The Lancet Neurology

Volumn 12, Issue 2, 2013, Pages 126-128

  Frisoni, Giovanni B ^a   Blennow, Kaj ^b  

^a IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; SOLANEZUMAB; TAU PROTEIN;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID; HUMAN; LETTER; NUCLEAR MAGNETIC RESONANCE IMAGING; PASSIVE IMMUNIZATION; PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; HUMANS; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS;

EID: 84872402283     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(12)70305-8     Document Type: Letter

References (15)

1. Jack CR, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010, 9:119-128.
2. Jack CR, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:257-262.
3. Jack CR, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013, 12:207-216.
4. EMA/CHMP/SAWP/893622/2011 Committee for Medicinal Products for Human Use (CHMP), (accessed Dec 20, 2012). http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/document/document_detail.jsp?webContentId=WC500118365&mid=WC0b01ac058009a3dc.
5. EMA/CHMP/SAWP/809208/2011 Committee for Medicinal Products for Human Use (CHMP), (accessed Dec 20, 2012). http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2011/12/WC500118737.pdf.
6. Fox NC, Cousens S, Scahill R, Harvey RJ, Rossor MN Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch Neurol 2000, 57:339-344.
7. Lorenzi M, Donohue M, Paternicò D, et al. Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment. Neurobiol Aging 2010, 31:1443-1451. for the Alzheimer's Disease Neuroimaging Initiative.
8. Braak H, Del Tredici K The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol 2011, 121:171-181.
9. Honer WG, Barr AM, Sawada K, et al. Cognitive reserve, presynaptic proteins and dementia in the elderly. Transl Psychiatry 2012, 2:e114.
10. Cavedo E, Galluzzi S, Pievani M, Boccardi M, Frisoni GB Norms for imaging markers of brain reserve. J Alzheimers Dis 2012, 31:623-633.
11. Fodero-Tavoletti MT, Okamura N, Furumoto S, et al. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. Brain 2011, 134:1089-1100.
12. Blennow K, Hampel H CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003, 2:605-613.
13. Wallin AK, Blennow K, Londos E, Minthon L, Hansson O CSF biomarkers predict a more malignant outcome in Alzheimer's disease. Neurology 2010, 74:1531-1537.
14. van Rossum IA, Vos SJB, Burns L, et al. Injury markers predict cognitive decline in subjects with MCI and amyloid pathology. Neurology 2012, 79:1809-1816.
15. Mattsson N, Portelius E, Rolstad S, et al. Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment. J Alzheimers Dis 2012, 30:767-768.